{"id":51824,"date":"2022-12-11T16:02:03","date_gmt":"2022-12-11T15:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wugen-presents-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/"},"modified":"2022-12-11T16:02:03","modified_gmt":"2022-12-11T15:02:03","slug":"wugen-presents-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wugen-presents-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","title":{"rendered":"Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting"},"content":{"rendered":"
\n

\n\u2013 <\/i>Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy \u2013<\/i>\n<\/p>\n

\n\u2013<\/i> <\/i><\/b>WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and metabolic flexibility \u2013<\/i>\n<\/p>\n

\n\u2013<\/i> <\/i><\/b>Phase 1 clinical study of WU-NK-101 for off-the-shelf treatment of patients with relapsed \/ refractory AML to begin in 1H2023 \u2013<\/i>\n<\/p>\n

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc.<\/a>, a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10 \u2013 13, 2022 in New Orleans, Louisiana.\n<\/p>\n

<\/a><\/p>\n

\n\u201cConventional NK cells (cNK) have proven dysfunctional in the harsh, acute myeloid leukemia (AML) tumor microenvironment (TME), and attempts to improve anti-tumor performance prior to adoptive transfer have proven limited in their success,\u201d said Sergio Rutella, M.D., Ph.D., FRCPath, FRSB, Professor of Cancer Immunotherapy at Nottingham Trent University and presenting author. \u201cThese data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed\/refractory (r\/r) AML. Further, the identification of a TME immune signature highly predictive of response may be an impactful tool to support future clinical studies.\u201d\n<\/p>\n

\n\u201cThese data further validate our approach deploying WU-NK-101 for AML,\u201d said Jan Davidson-Moncada, M.D., Ph.D., Chief Medical Officer of Wugen. \u201cIn early clinical studies, memory NK cells have already demonstrated impressive efficacy against AML. We look forward to building on those promising signals and advancing WU-NK-101 into the clinic as a novel, off-the-shelf therapy for this indication.\u201d\n<\/p>\n

\nToday\u2019s presentation highlighted the following:\n<\/p>\n